Investor Relations
Cassava Sciences, Inc. is a biopharmaceutical company that develops novel drugs.
First Phase 3 Study is Initiated to Evaluate Safety and Efficacy of Simufilam Over 52 Weeks in 750 Patients with Alzheimer’s Disease A Second Phase 3 Study, Expected to Begin by Year End, Will Evaluate Simufilam Over 78 Weeks In 1,000 Patients with Alzheimer’s Disease AUSTIN, Texas , Oct.
Cognition Scores Improved 3.2 Points on ADAS-Cog, Baseline to Month 12 (p